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Department of Veterans Affairs’’To the Editor:
I would like to thank Dr. Ross.
(5) $100 million for antiviral therapy over 20 months is $5 mil-
lion per month. This is clearly inadequate to treat 147,000
veterans with hepatitis C. This is why legislation should
be passed so that all veterans with HCV immediately pre-
qualify for their choice of Medicaid or Medicare. They could
then obtain antiviral therapy in the private sector instead of
waiting for the VA to treat 2% of them each year. Now,many
are trapped in the VA system while their curable infection
progresses to liver cancer, liver failure and death.
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Hepatitis C Treatment Centers, Louisville, KY, United States
E-mail addresses: bdceci33@iglou.com, bdceci01@me.comUse of TNFa antagonists in refractory AIH: Revealing the unforeseen(1) Dr. Ross does not state how many veterans with HCV are
currently receiving care at the Department of Veterans
Affairs (VA). In 2008, VHA clinicians cared for over
147,000 veterans with chronic HCV [1]. Treating 4500
patients with HCV in 20 months is only 225 patients per
month. The VA is currently treating less than 2% of infected
veterans per year with boceprevir and telaprevir. It will
take more than ﬁfty years for the VA to treat all of their
HCV infected patients. Evidence based care of an infectious
disease is cure of the infection not the development of
integrated models to address comorbidities. If 98% of
patients with a curable infection are not treated each year,
the VA’s response is inadequate.
(2) The VA does a better job with the human immunodeﬁ-
ciency virus (HIV) treating 78% of veterans [2]. The
number of patients on antiviral therapy clearly indicates
that HIV is a high priority for the VA while HCV treatment
is not.
(3) Telaprevir is not available as a non-formulary drug at the
Louisville VA. Boceprevir is on the formulary there.
(4) More than 1800 patients with HCV antibodies have been
identiﬁed at the Louisville VA over 19 years. They had mul-
tiple physicians providing care.To the Editor:
We read with considerable interest the paper by Weiler-Nor-
mann et al. in the Journal of Hepatology [1], which reported prom-
ising results regarding the use of inﬂiximab as a therapeutic
option in difﬁcult-to-treat patients with autoimmune hepatitis
(AIH). Although the exact role of tumor necrosis factor a (TNFa)
in the pathogenesis of AIH has not been elucidated yet, very
recently, it has been shown in a mouse model of fatal AIH that
TNFa is essential in the induction of AIH through upregulation
of hepatic CCL20 expression, which allows migration of dysregu-
lated splenic T cells [2]. As a consequence, the efﬁcacy of anti-
TNFa therapy in AIH could have a pathophysiological basis, tak-
ing also into account that TNFa is produced in large amounts in
the liver, in the context of AIH, by macrophages, CD8+ T cells
and possibly Th17 lymphocytes [3]. However, it is already known
from the use of anti-TNFa treatment in various autoimmune dis-
eases that anti-TNFa can also be immunogenic, with develop-
ment of either autoantibodies or true autoimmune diseases,
making inﬂiximab a two-edged sword [4].
The induction of AIH is one of the examples of the latter ‘‘ther-
apeutic paradox’’ during anti-TNFa treatment. In fact, the hepatic
ﬂare reported in the second patient of the study of Weiler-Nor-
mann et al. [1] could have been such an effect, especially if it
was combined with an IgG increase. Here, we are reporting an
additional case of a 30-year old female patient admitted to our
department because of inﬂiximab induced AIH, in an attempt to
further emphasize the ‘‘two-sided’’ face of anti-TNFa treatment.
Our patient had a history of refractory psoriasis treated with inf-
liximab (5 mg/kg at week 0, 2, 6 and then every 8 weeks by intra-
venous infusion) and presented to our department with an
asymptomatic transaminase ﬂare (ALT and AST >10  upper nor-
mal limit), 3 months after starting anti-TNFa therapy. Patient’s
history and extensive laboratory tests excluded genetic, toxic or
viral causes of acute hepatitis. Autoimmune serology revealed
anti-nuclear and anti-smooth muscle antibodies positivity (titers
1/640 and 1/320, respectively), with reactivity against F-actin.
Serum IgG levels were also elevated (1280 mg/dl before anti-
TNFa treatment; 1755 mg/dl at AIH diagnosis; upper normal
limit: 1600 mg/dl), while liver biopsy revealed moderate inter-
face hepatitis along with emperipolesis, hepatic rosette forma-
tion, drop out necrosis (replacement of dead hepatocytes by
inﬂammatory cells) and lymphoplasmocytic inﬁltrates in portal
tracts extending into the lobule. Taken together, all the above
gave a simpliﬁed score of 7, conﬁrming the diagnosis of deﬁnite
AIH [5]. Apart from inﬂiximab withdrawal, the patient was trea-
ted after an informed consent, according to our experience andJournal of Hepatology 2013 vol. 59 j 190–199 197
clinical practice [6], with prednisolone (initial dose 1 mg/kg/day)
plus mycophenolate mofetil (2 g/day), resulting in complete
remission of AIH within 2 months, as attested by normal trans-
aminases and IgG levels. Prednisolone was discontinued at the
4th month, but 2 months later a biochemical relapse was
observed (ALT and AST up to three times the upper normal limit
but normal IgG) and again prednisolone was started at a low dose
(20 mg/day). At the time of this writing (12 months from initial
treatment and 6 months from re-treatment), the patient has
complete response under mycophenolate monotherapy (3-month
prednisolone off treatment).
This report adds to a small but increasing number of pub-
lished cases of AIH induced by TNFa blockade, highlighting the
dual effects that anti-TNFa therapy might have, particularly in
the case of AIH [7,8]. The paradox of anti-TNFa therapy in AIH
is mainly attributed to the disruption of the regulatory role of
TNFa signaling on the immune system. TNFa blockade interferes
with the normal cytotoxic T lymphocyte suppression of self-reac-
tive B-cell population, leading to autoantibody production, a hall-
mark of AIH diagnosis, although from the pathophysiological
point of view the role of autoantibodies in AIH development is
obscure. Furthermore, anti-TNFa therapy disrupts the TNFa-
mediated apoptosis of activated T lymphocytes resulting in
unregulated lymphocyte activation [9].
Moreover, treatment with inﬂiximab predisposes patients to
severe infections, as clearly demonstrated by this series of Weil-
er-Normann et al. [1], where 7 out of 11 patients treated with inf-
liximab, had serious bacterial or viral infections. Indeed, the high
risk for serious infections is a well-recognized side effect of anti-
TNFa therapy in patients with rheumatoid arthritis or inﬂamma-
tory bowel disease [10]. However, the increased odds ratio might
be even more crucial in patients with advanced liver disease (in
this series [1], 7 out of 11 patients had histologically conﬁrmed
cirrhosis), since the already existing dysregulation of the immune
system due to cirrhosis, may further increase the risk of serious
infectious complications after anti-TNFa treatment.
Therefore, the induction of autoimmunity along with the pos-
sibility of lethal infections constitutes the ‘‘dark side’’ of anti-
TNFa therapy in AIH. In our opinion, TNFa blockade could be a
therapeutic option for refractory cases of AIH, taking into account
its reported efﬁcacy and the potential role of TNFa in the patho-
genesis of AIH [2,3]. However, we strongly believe that anti-TNFa
treatment for AIH could be a rational option only after alternative
regimens with a safer side-effect proﬁle, such as cyclosporine,
tacrolimus or mycophenolate mofetil [6] have failed. In any case,
the incapability to predict efﬁciently the ‘‘unforeseen complica-
tions’’ of such a treatment, such as the emergence of severe infec-
tions or, in particular, the development and/or deterioration of
autoimmunity, should be seriously weighted in the ﬁnal decision
of the clinician.
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Reply to: ‘‘Use of TNFa antagonists in refractory AIH: Revealing
the unforeseen’’
To the Editor:
We would like to thank Saitis and colleagues [1] for their view on
TNFa antagonist use in difﬁcult-to-treat autoimmune hepatitis
(AIH) and for the addition of pathophysiological mechanisms,
which may explain the effects of this treatment in AIH [2].
There are around 40 case reports in the literature – including
the most recent one presented here – that have described the
development of AIH or an immune mediated hepatitis after
administration of anti-TNFa agents such as inﬂiximab [3], ada-
limumab [4] and etanercept [5]. Whether the induction of AIH
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